JOSE L. CAMPRA, M.D.; EDWIN M. HAMLIN JR, M.D.; ROBERT J. KIRSHBAUM, M.D.; MICHEL OLIVIER, M.D.; ALLAN G. REDEKER, M.D.; TELFER B. REYNOLDS, M.D.
Forty-five hospitalized patients with severe acute alcoholic hepatitis were included in a prospective controlled trial of treatment with prednisone, 0.5 mg/kg body weight daily for 3 weeks, and then 0.25 mg/kg body weight daily for an additional 3 weeks. Mortality was 36% in prednisone-treated patients and 35% in control patients. No differences were found between the treated and control patients in duration of hospitalization or rate of improvement in serum bilirubin, glutamic-oxalacetic transaminase, or prothrombin time. Serum albumin levels increased to a greater degree in prednisone-treated patients, but this was thought to be caused by a nonspecific effect of corticosteroid on albumin synthesis.
CAMPRA JL, HAMLIN EM, KIRSHBAUM RJ, OLIVIER M, REDEKER AG, REYNOLDS TB. Prednisone Therapy of Acute Alcoholic Hepatitis: Report of a Controlled Trial. Ann Intern Med. ;79:625–631. doi: 10.7326/0003-4819-79-5-625
Download citation file:
Published: Ann Intern Med. 1973;79(5):625-631.
Gastroenterology/Hepatology, Liver Disease, Tobacco, Alcohol, and Other Substance Abuse.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use